Belvedere Trading
ADPT icon

Belvedere Trading’s Adaptive Biotechnologies ADPT Stock Holding History

Belvedere Trading’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-986
Closed -$7.53K – 886
2022
Q4 		$7.53K Buy
+986
New +$7.67K ﹤0.01% 936
2022
Q3 		– Sell
-15,889
Closed -$146K – 262
2022
Q2 		$146K Buy
+15,889
New +$140K ﹤0.01% 212

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Belvedere Trading's ADPT Position: Q1 2023 in Review

Belvedere Trading sold out of Adaptive Biotechnologies (ADPT) in Q1 2023, closing a stake of 986 shares — an estimated $7.53K sold.

Belvedere Trading first reported a position in ADPT in Q2 2022 and held it in 2 quarters. The position peaked at $146K in Q2 2022. 226 funds tracked by Wall St. Rank hold ADPT as of Q1 2023.

  • Belvedere Trading reported no remaining Adaptive Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 986 Adaptive Biotechnologies shares in Q1 2023, an estimated $7.53K.
  • Belvedere Trading first reported a position in Adaptive Biotechnologies in Q2 2022 and held it in 2 quarters.
  • Belvedere Trading's Adaptive Biotechnologies position peaked at $146K in Q2 2022.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.